Von Willebrand disease
blood-clotting disorder
Von Willebrand disease (VWD) is a type of blood-clotting disorder. It is the most common hereditary coagulopathy in humans, affecting 1% of the population. An acquired form of VWD can sometimes result from other medical conditions. Most people with VWD have no symptoms. Those that do usually have bleeding of varying intensity, including repeated bruising and nosebleeds.
VWD arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a protein required for platelet adhesion through the binding to other proteins, particularly factor VIII. The disease is known to affect several breeds of dogs as well as humans. Four types of hereditary VWD have been described, including platelet-type VWD, with VWD type 1 being the most common. Types 1 and 2 are inherited through an autosomal dominant pattern, meaning at least one parent must also have the disease.
Diagnosis is typically confirmed through blood tests. Managing VWD includes the use of desmopressin after minor trauma or before surgery, which allows the body to release more VWF. The disease is named after the Finnish physician Erik Adolf von Willebrand, who first described the condition in 1926.
“Von Willebrand disease” enters the record as blood-clotting disorder. Crown Archives preserves that source wording while asking what Willebrand, disease and blood-clotting can confirm, complicate or overturn.
Why this record matters
“Von Willebrand disease” is worth following because a concise public description often conceals a longer documentary argument. Here, Willebrand, disease and blood-clotting provides the most credible route into that argument.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Sep 7, 2026. The linked authority identifier is Q709360. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1926.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Von Willebrand disease”, its source revision and the description used here.
- Expand the search: follow Von Willebrand disease primary sources, Von Willebrand disease archive and Willebrand research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Von Willebrand disease”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Von Willebrand disease” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.